Skip to content
ENTXEntera Bio Ltd.

Earnings

When Entera Bio Ltd. reports, what it reported each quarter, and how the stock took the results.

25 quarters. Jun 30, 2019 to Sep 30, 2026. USD.

Next results · Q4 2026Projected

Mar 26, after the close

Fri, Mar 26, 2027in 128 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Mar 5 – Apr 2

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
$0.00
Revenue, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 −100.0%, Q4 2025 −100.0%
Net income
-$3.02M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 +57.1%, Q2 2026 +133.3%, Q1 2026 +16.7%, Q3 2025 −12.5%

Quarter by quarter

Q3 2026$0.00No Q3 2025 on file

Latest results

  1. Q3 2026Nov 6, 2026, after the closeThe release+2.5%by the close of Nov 9
    Revenue
    $0.00
    —
    Net income
    -$15.60M
    N/M
    EPS
    $0.11
    +57.1%
    Read · nothing to show
  2. Q2 2026Aug 7, 2026, after the closeThe release+7.0%by the close of Aug 10
    Revenue
    $0.00
    —
    Net income
    -$7.31M
    N/M
    EPS
    $0.14
    +133.3%
  3. Q1 2026May 8, 2026, after the closeThe release5.5%by the close of May 11
    Revenue
    $0.00
    −100.0%
    Net income
    -$3.51M
    N/M
    EPS
    $0.07
    +16.7%
  4. Q4 2025Mar 27, 2026, after the closeThe release10.3%by the close of Mar 30
    Revenue
    $0.00
    −100.0%
    Net income
    -$3.02M
    N/M
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Nov 6, 2026 · after-hoursNov 6, 202637 d10-Q$0.00—$0.11+2.5%
Q2 2026Jun 30, 2026Aug 7, 2026 · after-hoursAug 7, 202638 d10-Q$0.00—$0.14+7.0%
Q1 2026Mar 31, 2026May 8, 2026 · after-hoursMay 8, 202638 d10-Q$0.00−100.0%$0.075.5%
FY 2025
Q4 2025derivedDec 31, 2025Mar 27, 2026 · after-hoursMar 27, 202686 d10-K$0.00−100.0%—10.3%
Q3 2025Sep 30, 2025Nov 14, 2025 · after-hoursNov 14, 202545 d10-Q$0.00−100.0%$0.071.8%
Q2 2025Jun 30, 2025Aug 8, 2025 · after-hoursAug 8, 202539 d10-Q$0.00−100.0%$0.06+3.6%
Q1 2025Mar 31, 2025May 9, 2025 · after-hoursMay 9, 202539 d10-Q$42.00K—$0.062.3%
FY 2024
Q4 2024derivedDec 31, 2024Mar 28, 2025 · after-hoursMar 28, 202587 d10-K$82.00K——2.9%
Q3 2024Sep 30, 2024Nov 8, 2024 · after-hoursNov 8, 202439 d10-Q$42.00K—$0.082.9%
Q2 2024Jun 30, 2024Aug 9, 2024 · after-hoursAug 9, 202440 d10-Q$57.00K—$0.06—
Q1 2024Mar 31, 2024May 10, 2024 · after-hoursMay 10, 202440 d10-Q$0.00—$0.054.9%
Earlier years, FY 2019 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 6, 2026005057
10-QAug 7, 2026003947
10-QMay 8, 2026002458
10-KMar 27, 2026001797
10-QNov 14, 2025003852
10-QAug 8, 2025002702
10-QMay 9, 2025001674
10-KMar 28, 2025001112
10-QNov 8, 2024003558
10-QAug 9, 2024002522

Provenance

ProvenanceData status and checks

Entera Bio Ltd. · CIK 1638097 · Engraved from SEC EDGAR